KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Efficacy and Safety of Pimodivir Combined With Standard of Care in Hospitalized and Nonhospitalized High-Risk Adolescents and Adults With Influenza A Infection.

Lorant Leopold, Johan Vingerhoets, Sofie Deleu, Catherine Nalpas, Karin Weber, Ilse van Dromme, David Lowson, Bart Michiels, Wilbert van Duijnhoven

J Infect Dis 231(1) e132-e143

PMID39172627
PMCIDPMC11793051
DOI10.1093/infdis/jiae408
发表日期2024-08-22
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: An unmet need exists for effective antivirals to treat patients hospitalized with influenza. The results of 2 phase 3 studies that evaluated the efficacy and safety of pimodivir in combination with investigator-chosen standard of care (SoC) treatment are presented. METHODS: Hospitalized patients (hospital study; NCT03376321) and high-risk outpatients (outpatient study; NCT03381196) with laboratory-confirmed influenza A infection were randomized 1:1 to 600 mg pimodivir twice daily + SoC or placebo twice daily + SoC for 5 days. For most patients, SoC included oseltamivir. Primary end points were Hospital Recovery Scale (HRS) at day 6 (hospital study) and median time to resolution (TTR) of influenza-related symptoms (outpatient study). RESULTS: Pimodivir + SoC (oseltamivir) treatment showed no clinical benefit over placebo + SoC on HRS at day 6 (common odds ratio, 0.943; 95% confidence interval [CI], .609-1.462; P = .397; hospital study). A shorter median TTR of 7 symptoms was estimated with pimodivir + SoC versus placebo (92.6 hours; 95% CI, 77.6-104.2 vs 105.1 hours; 95% CI, 92.7-128.6; P = .0216; outpatient study). CONCLUSIONS: Pimodivir + SoC showed no additional clinical benefit versus SoC treatment alone in hospitalized patients. Pimodivir + SoC demonstrated shorter TTR of influenza symptoms versus placebo + SoC in high-risk outpatients. CLINICAL TRIAL REGISTRATION: NCT03376321 and NCT03381196.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。